Coeptis Therapeutics — Investor Presentation (June 2023)
29 slides from Coeptis Therapeutics's investor presentation, Jun 6, 2023

Slide 1: Coeptis Therapeutics Holdings, Inc. Corporate Overview
1 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Coeptis Therapeutics Holdings, Inc. Corporate Overview NASDAQ: COEP C10050 V4.0 18 - May 2023

Slide 2: Cautionary Note Regarding Forward-Looking Statements
2 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Cautionary Note Regarding Forward - Looking Statements Certain statements in this Presentation, and statements by management or other persons acting by or on behalf of Coeptis made in connection with this Presentation, constitute “forw

Slide 3: Important Legal Disclaimers
3 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Important Legal Disclaimers No Offer or Solicitation: This Presentation is for informational purposes and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any security of Coeptis,

Slide 4: Important Legal Disclaimers cont'd.
4 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Important Legal Disclaimers cont’d. This Presentation is not a substitute for any other document that Coeptis may file with the SEC, and this Presentation is qua lif ied in its entirety by such SEC filings. Readers may obtain free copi

Slide 5: Risk Factors
5 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Risk Factors There are a number of risks related to us and our operations. You should carefully review the risks described in “Risk Facto rs and Special Considerations” beginning on page 13 of the preliminary prospectus. If any of thes

Slide 6: Coeptis Therapeutics
6 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved COEPTIS THERAPEUTICS We are a Pittsburgh, PA based biotechnology company founded by an experienced team developing innovative cell therapy platforms in oncology .

Slide 7: Corporate Highlights
7 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Corporate Highlights GEAR ۲ cell therapy and in vitro diagnostic platforms GEAR - NK enables development of modified NK cell - based therapeutics optimized to be co - administered with targeted antibodies. CD38 - GEAR - NK in developme

Slide 8: Clinical Pipeline
8 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Clinical Pipeline Phase III PHASE II PHASE I PRE - CLINICAL TARGET INDICATION PROGRAM Current Protect CD38+ NK Cells from destruction by anti - CD38 monoclonal antibodies CD38 - GEAR - NK CAR - T cells co - administered with one or mor

Slide 9: Anticipated Development Plans
9 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Anticipated Development Plans • Advance CD38 - GEAR - NK to the clinic for the treatment of multiple myeloma • Expand the GEAR Platform into new cell therapy products GEAR • Expand existing sponsored Research Agreement with the Univers

Slide 10: Deverra Therapeutics Opportunity
10 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Deverra Therapeutics Opportunity* ALLOGENEIC IMMUNO - ONCOLOGY PLATFORM *Coeptis has exclusive rights through August 31, 2023 to acquire, subject to satisfaction of numerous closing conditions, cer tai n assets of Deverra

Slide 11: Value Drivers & Potential Advantages
11 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Deverra R&D programs, extensive global IP, and established simplified, reproducible and scalable allo immune cell manufacturing platform , align with Coeptis’ existing portfolio and further development of their other pre - clinical pr

Slide 12: Differentiated from Other Allogeneic Cell Therapy Companies
12 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Differentiated from Other Allogeneic Cell Therapy Companies ImmunityBio NKarta, Indapta, Gamida* FATE, Shoreline, Century CytoImmune, Artiva, Glycostem Deverra NK92 Immortalized Cancer Cell Line Healthy Adult Donor PBMCs iPSCs Cord Bl

Slide 13: DVX201 – Clinical Program
13 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved DVX201 – Clinical Program Phase 1 Study: Safety and Efficacy of Allogeneic NK Cell Infusions in Patients with Relapsed / Refractory AML and High Risk MDS • Multiple dose, MTD study (2 doses/patient) • PI: Dr. Tom LeBlanc, Duke Univers

Slide 14: Coeptis - Deverra Opportunity
14 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved • 4M common shares of COEP • Up to $1.5M of cash The transaction would provide Coeptis with exclusive rights to : • DVX201, a clinical - stage, unmodified natural killer (NK) cell therapy, which is currently the subject of two Phase 1

Slide 15: GEAR Enabling Potent Combinatorial Immuno-Oncology Treatment Strategies
15 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved GEAR ۲ Enabling Potent Combinatorial Immuno - Oncology Treatment Strategies

Slide 16: GEAR-NK (CD38) Strategy
16 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved IMMUNOTHERAPY CHALLENGES Various immunotherapies for CD38+ tumors are designed to find and kill cells that express the CD38 antigen; therefore, CD38+ NK cells are likely to become collateral damage and with their eradication, the over

Slide 17: Current Anti-CD38 Pathway vs Pathway with GEAR-NK (CD38)
17 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Animations herein are provided as visual aids to help articulate hypothesized proof - of - concept in a general manner and do not de pict precise scientific mechanisms - of - action. Anti - CD38 mAbs (Infused antibodies from current c

Slide 18: CD38-GEAR-NK – Market Opportunity
18 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved CD38 - GEAR - NK – Market Opportunity CD38 - GEAR - NK could change how CD38 - related cancers are treated by protecting CD38+ NK cells from destruction by anti - CD38 mAbs. Potential opportunity to improve the treatment of CD38 - rel

Slide 19: Coeptis Collaboration – VyGen-Bio
19 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Coeptis has obtained the exclusive right to negotiate towards the acquisition of VyGen - Bio, Inc. or its assets, including IP and know how related to rights to the GEAR ۲ cell therapy and companion diagnostic platforms. Transaction w

Slide 20: GEAR Potential Advantages
20 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved GEAR is novel cell engineering approach that protects the integrity, fitness and function of the cell while importantly shielding it from destruction by co - administered mAbs. POTENTIAL ADVANTAGES 1 2 3 GEAR platform offers the poten

Slide 21: SNAP-CAR A Multi-Antigen CAR T Platform
21 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved SNAP - CAR A MULTI - ANTIGEN CAR T PLATFORM

Slide 22: CAR T Platform – Market Opportunities
22 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved CAR T Platform – Market Opportunities CAR T offers the potential to revolutionize cancer treatment; however, we believe there are opportunities to improve upon current CAR T therapies that could enable the potential application of the

Slide 23: Immunotherapy Challenges
23 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved IMMUNOTHERAPY CHALLENGES Reducing potential toxicity: The therapeutic activity of the SNAP - CAR T cells can be controlled by the antibody dose, which we envision would allow clinicians to potentially mitigate toxicity from over - act

Slide 24: SNAP-CAR – Potential Advantages
24 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved SNAP - CAR T cells can be controlled by the antibody dose, which may allow clinicians to potentially reduce toxicity from over - activity. Potential to minimize cancer relapse by combining SNAP - CAR T cells with antibodies targeting

Slide 25: Coeptis Management Team
25 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved COEPTIS MANAGEMENT TEAM Dave Mehalick Co - Founder, President & CEO 30 years of diverse business experience in healthcare, information technology and finance including consulting, capital markets, private equity, and investments Chris

Slide 26: Coeptis Scientific Advisory Board
26 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Coeptis Scientific Advisory Board Head of the Gene and Cell Therapy Group, Division of Hematology, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm Evren Alici M.D., Ph.D. Arnika K. Wagner, Ph.D

Slide 27: Financials & Capitalization
27 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Financials & Capitalization Common Equivalents Securities (April 24, 2023) 21,441,036 Common Stock 1 1,357,500 Options (WAEP $1.63) 100,000 Options ($10.00) 9,413,912 Warrants (WAEP $10.55) 2 32,312,448 Fully Diluted $2.1M Cash (3/31/

Slide 28: Coeptis Investment Thesis
28 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Cell and gene therapies have the potential to “disrupt” current treatment paradigms. Early - stage development assets in this space are being routinely acquired by larger pharma companies. CAR T technologies being developed at Univers

Slide 29: Coeptis Investor Relations Contact
29 © 2023 Coeptis Therapeutics Holdings, Inc. All rights reserved Coeptis Investor Relations Contact: Daniel Kontoh - Boateng Tiberend Strategic Advisors dboateng@tiberend.com coeptistx.com
Source: SEC EDGAR · 8-K filed Jun 6, 2023
More decks from Coeptis Therapeutics Inc
Investor Presentation (December 2023)20 slides · Dec 5, 2023
Investor Presentation (November 2022)27 slides · Nov 3, 2022
SPAC Merger (September 2022)30 slides · Sep 21, 2022
SPAC Merger (September 2022)29 slides · Sep 7, 2022
SPAC Merger (July 2022)31 slides · Jul 6, 2022
Bull Horn Holdings — SPAC Merger (July 2022)31 slides · Jul 6, 2022